PLX Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -10571.43%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat AIM ImmunoTech's return on equity of -256.33%.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 539.54%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than Protalix Biotherapeutics, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.248, which suggesting that the stock is 124.798% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 24.75x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.19x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -2301.55%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 539.54%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 50.25%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.248, which suggesting that the stock is 124.798% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 24.75x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.19x versus 49.69x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Curis, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of -243.36%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Curis, Inc.'s return on equity of -461.34%.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 539.54%. On the other hand Curis, Inc. has an analysts' consensus of $16.33 which suggests that it could grow by 1206.67%. Given that Curis, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Curis, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.248, which suggesting that the stock is 124.798% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 4.025, suggesting its more volatile than the S&P 500 by 302.512%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is higher than Curis, Inc.'s net income of -$7.7M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 24.75x while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.19x versus 1.19x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics, Inc. has a net margin of 13.19% compared to Protalix Biotherapeutics, Inc.'s net margin of 49.46%. Protalix Biotherapeutics, Inc.'s return on equity of 12.06% beat Halozyme Therapeutics, Inc.'s return on equity of 139.43%.

Protalix Biotherapeutics, Inc. has a consensus price target of $11.00, signalling upside risk potential of 539.54%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $76.00 which suggests that it could grow by 17.54%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Halozyme Therapeutics, Inc..

Protalix Biotherapeutics, Inc. has a beta of -0.248, which suggesting that the stock is 124.798% less volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.224%.

Protalix Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix Biotherapeutics, Inc. pays -- of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.

Protalix Biotherapeutics, Inc. quarterly revenues are $17.9M, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $354.3M. Protalix Biotherapeutics, Inc.'s net income of $2.4M is lower than Halozyme Therapeutics, Inc.'s net income of $175.2M. Notably, Protalix Biotherapeutics, Inc.'s price-to-earnings ratio is 24.75x while Halozyme Therapeutics, Inc.'s PE ratio is 13.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix Biotherapeutics, Inc. is 2.19x versus 6.53x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.